THYROID CANCERS

During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.

In an interview with Targeted Oncology™, R. Michael Tuttle, MD, discussed the plethora of treatment options for thyroid cancer as well as overtreatment and undertreatment of the disease.

Advances in thyroid cancer to date hold promise for other orphan cancers with analogous alterations, on which we might bring to bear agents that will have similar effects.

In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions

Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.

Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.

In an interview with Targeted Oncology, Jennifer Hong Kuo, MD, discussed the use of radiofrequency ablation to treat thyroid nodules and how research from Columbia University will guide further research around this topic

An extended follow-up of the phase 3 COSMIC-311 trial supported the use of cabozantinib to treat patients with radioiodine-refractory differentiated thyroid cancer, irrespective of the duration of prior lenvatinib received.

Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.

Investigators found that higher body mass index is associated with more aggressive differentiated thyroid carcinoma tumors, as well as an increased risk for worse clinical outcomes, with patients with a BMI above 28.4 being at a higher risk.

Stephen J. Chanock, MD, discusses the background of the Chernobyl accident and its association with thyroid cancer.

A real-world retrospective patient chart review showed a 72.4% physician-reported best overall response, confirming the agent’s clinical efficacy to treat patients with RAI-refractory differentiated thyroid cancer.

A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.

A prospective study of blood samples confirmed the immune-modulatory effect of lenvatinib with a significant increase in the peripheral natural killer cells among patients with advanced thyroid cancer.

Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.

The combination use of a BRAF/MEK inhibitor plus checkpoint inhibitor immunotherapy did not meet median overall survival at 2 years, hinting at the combinations’ improved efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer.

In an interview with Targeted Oncology, Larisa Greenberg, MD discussed the current state of thyroid cancer, challenges, and where the field is headed in the near future.

Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.

For Thyroid Cancer Awareness Month, Warren C. Swegal, MD, highlights the changing landscape, important trials, sequencing, and future of this setting.

The use of immune checkpoint inhibitors in anaplastic thyroid cancer shows a similar toxicity profile to that seen in PD-1 and PD-L1 targeting therapies.

In an interview with Targeted Oncology following the tweet chat, Warren Swegal, MD, discussed the key takeaways from the discussion, including his thoughts on the case and what he hopes will be addressed in the future of the thyroid cancer space.

The experimental combination of tremelimumab, durvalumab, and stereotactic body radiotherapy lack overall surival benefit in anaplastic thryoid cancer, phase 1 findings show.

Focused cancer centers increased hemithyroidectomy 2 years prior to the release of the newest American Thyroid Association guidelines. However, only community cancer program hospitals began to increase hemithyroidectomy utilization following release of guidelines.

Data from the phase 3 ASTRA study show that selumetinib does not induce a complete remission in patients with differentiated thyroid cancer.

Nathan Pennell, MD, PhD, discusses a first-in-human trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

Lori J. Wirth, MD, discusses the treatment options now available for patients with iodine-refractory differentiated thyroid cancer.

During a Targeted Oncology case-based roundtable event, Krzysztof J. Misiukiewicz, MD, discussed deciding to use NTRK inhibitor for the treatment of a 67-year-old woman with thyroid cancer.

Continuing to monitor trends will be important in regard to the American Thyroid Association developing other updates to its thyroid cancer treatment guidelines and trends.

In this companion article, David S. Hong, MD, considers the safety and efficacy of the first-generation TRK inhibitor larotrectinib and discusses how acquired resistance may affect research into second-generation agents.

Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.